Evidence map›Paper›PMID 29062170›Full record

ArticleIndian journal of clinical biochemistry : IJCB2017

Diseases and Molecular Diagnostics: A Step Closer to Precision Medicine.

Shailendra Dwivedi, Purvi Purohit, Radhieka Misra, Puneet Pareek, Apul Goel, Sanjay Khattri, Kamlesh Kumar Pant, Sanjeev Misra, Praveen Sharma

Abstract readEditorial
In one paragraph

Article in Indian journal of clinical biochemistry : IJCB, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shailendra DwivediDepartment of Biochemistry, All India Institute of Medical Sciences, Jodhpur, 342005 India.
Purvi PurohitDepartment of Biochemistry, All India Institute of Medical Sciences, Jodhpur, 342005 India.
Radhieka MisraEra's Lucknow Medical College and Hospital, Lucknow, 226003 India.
Puneet PareekDepartment of Radio-Therapy, All India Institute of Medical Sciences, Jodhpur, 342005 India.
Apul GoelDepartment of Urology, King George Medical University, Lucknow, 226003 India.
Sanjay KhattriDepartment of Pharmacology and Therapeutics, King George Medical University, Lucknow, 226003 India.
Kamlesh Kumar PantDepartment of Pharmacology and Therapeutics, King George Medical University, Lucknow, 226003 India.
Sanjeev MisraDepartment of Surgical Oncology, All India Institute of Medical Sciences, Jodhpur, 342005 India.
Praveen SharmaDepartment of Biochemistry, All India Institute of Medical Sciences, Jodhpur, 342005 India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current advent of molecular technologies together with a multidisciplinary interplay of several fields led to the development of genomics, which concentrates on the detection of pathogenic events at the genome level. The structural and functional genomics approaches have now pinpointed the technical challenge in the exploration of disease-related genes and the recognition of their structural alterations or elucidation of gene function. Various promising technologies and diagnostic applications of structural genomics are currently preparing a large database of disease-genes, genetic alterations etc., by mutation scanning and DNA chip technology. Further the functional genomics also exploring the expression genetics (hybridization-, PCR- and sequence-based technologies), two-hybrid technology, next generation sequencing with Bioinformatics and computational biology. Advances in microarray "chip" technology as microarrays have allowed the parallel analysis of gene expression patterns of thousands of genes simultaneously. Sequence information collected from the genomes of many individuals is leading to the rapid discovery of single nucleotide polymorphisms or SNPs. Further advances of genetic engineering have also revolutionized immunoassay biotechnology via engineering of antibody-encoding genes and the phage display technology. The Biotechnology plays an important role in the development of diagnostic assays in response to an outbreak or critical disease response need. However, there is also need to pinpoint various obstacles and issues related to the commercialization and widespread dispersal of genetic knowledge derived from the exploitation of the biotechnology industry and the development and marketing of diagnostic services. Implementation of genetic criteria for patient selection and individual assessment of the risks and benefits of treatment emerges as a major challenge to the pharmaceutical industry. Thus this field is revolutionizing current era and further it may open new vistas in the field of disease management.

Indexed as

Genetic diseases and disordersMolecular diagnosticsMolecular signatureMolecular techniquesPrecision medicine

Identifiers

PMID29062170
PMCPMC5634985

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.